Details
In this analysis, we compared the risk of inflammatory bowel disease (IBD) among new users of dipeptidyl peptidase-4 inhibitors (DPP-4i) versus new users of sodium-glucose costransporter-2 inhibitors (SGLT2i) and sulfonylureas (SU), separately, in the Sentinel Distributed Database (SDD).
We identified individuals with new use of DPP-4i or SGLT2i/SU and evaluated the occurrence of incident IBD during exposure episodes among a cohort who were at least 18 years of age and had evidence of type 2 diabetes mellitus. We then conducted a Propensity Score Analysis (PSA) comparing the two exposure groups after inverse probability weighting on the propensity score.
We distributed this request to six Sentinel Data Partners on March 17, 2025. The study period includes data from March 29, 2013, through August 31, 2024.
The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.